ALKS / Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. more_horizontal

Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a clinical update announced more_horizontal

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment. more_horizontal

Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through more_horizontal

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. Th more_horizontal

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Tev more_horizontal

Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a more_horizontal

Alkermes plc (NASDAQ:ALKS ) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Cor more_horizontal